Sincere thanks to our members who reviewed the performance of the FSH Society and helped us earn our fifth consecutive Top-rated Great Nonprofits badge! We work hard for all of you, and it inspires our team to redouble our efforts when you give us so much encouragement! Thank you!
The FSH muscular dystrophy scientific literature finally has a publication describing a genetic mouse model that develops skeletal muscle disease. This work comes via the laboratory of Michael Kyba, PhD, at the University of Minnesota’s Lillehei Heart Institute. This murine model, called iDUX4 pA, has a number of compelling similarities to the human disease. Ever… Read More »
UPDATED October 30, 2017 Researchers at the University of Rochester in New York are conducting a research study to learn more about a potential symptomatic therapy for FSHD. This study may help determine if a combination of drugs (recombinant human growth hormone [rHGH] and testosterone) can be safely given to patients with FSHD and possibly… Read More »
Youngest member, with a passion for advocacy and fundraising The FSH Society is pleased to announce that Carden Wyckoff was elected to serve on the Board of Directors on September 26, 2017. In joining the Board just two years after graduating from college, she becomes the youngest director in the history of the Society. Carden… Read More »
Q&A With Dr. Yi-Wen Chen by JIM ALBERT, Eldersburg, Maryland Antisense therapy is a form of treatment for genetic disorders. In the past year antisense drugs have been approved by the FDA for the treatment of two types of muscular dystrophies: some forms of Duchenne muscular dystrophy, and spinal muscular atrophy. While antisense therapy for the… Read More »